1346-P: Obesity and Type 2 Diabetes in Patients with NAFLD Are Independently Associated with the Risk of Liver Fibrosis, Insulin Resistance, and Atherogenic Dyslipidemia

Obesity (OB) and type 2 diabetes (T2D) are associated with NAFLD and a worse cardiometabolic profile. However, their independent contribution to steatosis, fibrosis, insulin resistance (IR) and atherogenic dyslipidemia are controversial. To this end, we examined the prevalence of NAFLD and hepatic fibrosis in 199 patients (64 with T2D, 135 without T2D) screened from outpatient endocrinology and primary care clinics. NAFLD/fibrosis was assessed by transient elastography (liver fat by controlled attenuation parameter/CAP; fibrosis by liver stiffness measurement/LSM) . Patients were divided into groups either with or without obesity (OB) or T2D. Within each group, patients were well matched for age, BMI, A1c and AST/ALT. The impact of obesity was best observed on the prevalence of steatosis, that increased from pts without OB or T2D (controls = C) to OB/no-T2D (OB) and OB/T2D (C: 40% vs. OB: 64% vs. OB/T2D: 86%, both p